Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer receives EU approval for Dupuytren’s contracture treatment

Pfizer receives EU approval for Dupuytren’s contracture treatment

1st March 2011

Pfizer has been granted regulatory clearance to launch Xiapex, a new treatment for the connective tissue disorder Dupuytren's contracture, in Europe.

The European Commission has approved the collagenase clostridium histolyticum therapy for sale based on positive data from two pivotal placebo-controlled clinical trials.

It represents the first injectable treatment to be approved in the EU for Dupuytren's disease, which affects 13 percent of the population and can cause fingers to become bent towards the palm of the hand.

The drug has been developed by Auxilium Pharmaceuticals, which will be responsible for launching the product in all global territories other than Europe.

Geno Germano, president and general manager for specialty care and oncology at Pfizer, said: "The EU approval of this treatment for Dupuytren's contracture is a testament to Pfizer's commitment to bringing innovative medicines to patients."

Last month, Pfizer announced that it will be taking control of the consumer health business of European company Ferrosan as it looks to expand its market reach.ADNFCR-8000103-ID-800434751-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.